RPN2 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis Via the PI3K-Akt Pathway

Chenglin Han,Shuxiao Chen,Haiyang Ma,Xiangchuan Wen,Zilong Wang,Yingkun Xu,Xunbo Jin,Xiao Yu,Muwen Wang
DOI: https://doi.org/10.2147/ott.s300480
IF: 4
2021-01-01
OncoTargets and Therapy
Abstract:BACKGROUND:Ribophorin II (RPN2) is a highly conserved glycoprotein involved in the N-linked glycosylation of multiple proteins. RPN2 was reported to be associated with malignant phenotype in several tumors. However, the function of RPN2 in bladder cancer (BCa) remains unclear.METHODS:Expression of RPN2 in BCa and adjacent tissues was compared by bioinformatics analysis, immunohistochemistry, and Western blotting. qRT-PCR was performed to explore the correlation between RPN2 expression and various clinical features in 38 patients. We assessed the effects of RPN2 on the biological activity of BCa both in vitro and in vivo, and explored its potential mechanisms based on gene set enrichment analysis (GSEA).RESULTS:We found that RPN2 was highly expressed in human BCa compared with normal adjacent tissues. There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa. We further demonstrated that RPN2 silencing inhibited the growth and metastasis of BCa both in vitro and in vivo. Western blotting revealed that RPN2 knockdown suppressed epithelial-mesenchymal transition (EMT) and inhibited the PI3K-Akt pathway.CONCLUSION:These data suggest that RPN2 functions as an oncogene to promote tumor development and is a promising prognostic factor and therapeutic target in BCa.
What problem does this paper attempt to address?